CEO, President, Chairman, and Co-Founder
Colin Hill co-founded GNS Healthcare in 2000 and has served as CEO since then. He brings years of hands-on scientific experience to his role, with expertise in the areas of computational physics and systems biology. He also serves as Chairman of GNS Healthcare’s parent company Via Science, a leading big data analytics company focused on business intelligence, finance, and economic forecasting. He also serves on the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease. Colin serves on the Advisory Board of the Boston Medical Center’s philanthropic trust and as the Chair of the Industrial Advisory Board of EBICS. Colin is the author of the “Healthcare 2020” blog on Forbes.com.
In 2004, Colin was named to MIT Technology Review’s TR100 list of the top innovators in the world under the age of 35. He is a frequent speaker at international scientific and industry conferences and has appeared in numerous publications and television segments, including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist. He graduated from Virginia Tech with a degree in physics and earned masters degrees in physics from McGill University and Cornell University.
Chief Operating Officer and Chief Financial Officer
David Burke is highly involved in the financial, administrative, and budget decisions at GNS Healthcare, as well as the planning and execution of new corporate initiatives.
David has extensive experience in the formation, capitalization, management, and disposition of high growth, entrepreneurial businesses in healthcare analytics, professional services, product development, internet, and other industries. He also has experience in senior housing, including the development of large scale independent living, assisted living, skilled nursing, and cognitive care facilities. Prior to joining GNS Healthcare, David served as CFO of healthcare analytics leader QualityMetric Incorporated (QM), where he helped facilitate the framing and execution of the company’s strategy. This led to the company’s rapid growth and successful acquisition by Ingenix, a $1.8B subsidiary of United Health Group (NYSE: UNH). Prior to QM, David served as Director of Corporate Development at Item New Product Development, an integrated design, engineering, and contract supply company. During David’s tenure the firm achieved breakout growth and evolved from a general industry practice into a holding company with market-specialized subsidiaries, such as Ximedica, a medical device company.
David holds a BA from Harvard College and an MBA from Columbia Graduate School of Business.
Executive Vice President and Co-Founder
Iya Khalil is responsible for fostering and developing GNS Healthcare’s partnerships with pharma, biotech, and academia. In addition, she oversees the execution of projects in these areas.
She has extensive experience in creating and applying computational approaches that leverage large-scale genomic, clinical, and molecular data for healthcare innovation. Prior to joining GNS Healthcare, she worked at Cornell University, University of Washington, and Abbott Labs.
A frequent speaker at industry events and conferences, Iya is an inventor on a number of pending patents and has published multiple articles on in silico technologies applied to drug discovery and development. She is also a co-founder and board member of the New Libya Foundation, a non-profit organization dedicated to nurturing the development of civil society organizations in Libya. Iya holds a B.S. in physics from the University of Washington and a Ph.D. in physics from Cornell University.
Chief Strategy Officer
Carol McCall leads the development of new products and oversees the execution of projects for real world outcomes.
Carol is a health actuary with a background in innovation, predictive analytics and health services design. Her specialties are creating novel computational approaches that leverage big data in healthcare and designing services and business models that expand on the traditional notions of health, care, community and sustainability. Most recently, Carol served as Chief Innovation Officer at Tenzing Health, a subsidiary of Vanguard Health Systems, where she merged creative analytic approaches with innovations in health services that extended the dimensions of care, improved people’s health, and dramatically reduced their healthcare costs.
Prior to joining Tenzing, Carol led the R&D efforts in Humana’s Innovation Center, where she pioneered using sophisticated analytic techniques to build a portfolio of prediction, knowledge discovery, and simulation models. She also launched Humana’s innovations in personalized medicine and led Humana’s Health Services Research Center (HSRC), emphasizing research in population health, health outcomes, health economics, pharmacovigilance, and the psychology of health behavior change. She also served as Humana’s Chief Information Officer and as VP of Pharmacy Management. Outside of Humana, Carol served as EVP of Managed Care Business Development for Allscripts Healthcare Solutions and as an actuarial consultant for Milliman.
Carol also helped launch Green Ribbon Health, LLC a Florida-based company creating innovations in health support services for seniors in Tampa, and later served on their board of directors. She served as a member of the National Committee on Vital and Health Statistics (NCVHS), a member of the HSRC’s governing board, and as advisor to the HRP Scientific Program Board. Carol is a member of the American Academy of Actuaries and a Fellow of the Society of Actuaries. She received a B.S. in actuarial science from University of Iowa.
Executive Vice President, Corporate Development
Thomas Neyarapally leads GNS Healthcare’s business and corporate development activities, as well as the expansion, protection, and monetization of the company’s intellectual property.
Before joining GNS Healthcare, Thomas served as an associate in the New York office of the law firm Frommer, Lawrence & Haug LLP, where he focused on transactional, product development, and litigation matters in the pharmaceutical and biotech industries. Thomas was previously an associate in the corporate department practice at Chadbourne & Parke, LLP, and held the position of analyst at Arthur D. Little. While attending Cornell’s Johnson Graduate School of Management, he served as a partner with BR Ventures, the Johnson School’s student-run venture capital firm.
Thomas graduated from the University of Connecticut as an Honors Scholar with a B.S. in chemical engineering. He holds a J.D. and an M.B.A. from Cornell University and is a registered patent attorney.
Chief Mathematics Officer
Bruce Church is responsible for developing algorithms for REFS™ and leading projects for the development of new products and technologies.
An expert in statistical physics, machine learning, parallel computing, and causal modeling, Bruce helped develop the original REFS™ platform. He spent the previous decade at Cornell University, developing global optimization methods for computational protein folding, the results of which have been published in several peer-reviewed journals.
Bruce has been awarded and served as the principal investigator on several major grants, including a $2.5 million award from the Department of Energy. He has served on the Board of Directors for U.S. Rugby and coached the under-23 women’s Northeast rugby team. Bruce received a B.S. in applied and engineering physics and a Ph.D. in applied physics from Cornell University in Ithaca, New York.